- Home
- CGAU vs LGND Comparison
CGAU vs LGND Comparison
Compare CGAU & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | LGND |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | Canada | United States |
| Employees | N/A | 68 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGAU | LGND |
|---|---|---|
| Price | $16.74 | $195.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.00 | ★ $245.86 |
| AVG Volume (30 Days) | ★ 1.9M | 183.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.72 | $1.50 |
| Revenue Next Year | $13.78 | $18.28 |
| P/E Ratio | ★ $11.74 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $93.58 |
| 52 Week High | $21.17 | $227.92 |
Technical Indicators
Market Signals| Indicator | CGAU | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 44.28 |
| Support Level | $15.93 | $179.55 |
| Resistance Level | $20.49 | $207.72 |
| Average True Range (ATR) | 0.82 | 10.02 |
| MACD | -0.22 | -1.59 |
| Stochastic Oscillator | 28.91 | 3.39 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.